Clinical Trials

Accrual Status
Limit to SWOG Trials

654 Results

Active Filters

Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0221

"Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High -Risk Node Negative Breast Cancer"

Status Notes
Effective immediately, the following S0221 Forms must be submitted in iMedidata RAVE: Follow-up Form, Supplemental Follow-up Form, S0221Trastuzumab Use Form, Notice of Death, Consent Withdrawal, and Lost to Follow-up. Rationale for change in data submission procedure, RAVE access, and data submission instructions are included in the 9/1/2020 memorandum, accessible from: www.ctsu.org.
Research Committee(s)
Breast Cancer
Activated
11-01-2003
Closed
01-15-2012
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
62%
Published
SWOG Clinical Trial Number
S0331
Closed
Phase
Accrual
56%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0202
Closed
Phase
Accrual
63%
Published
SWOG Clinical Trial Number
S0222
Closed
Phase
Accrual
75%
Published
SWOG Clinical Trial Number
S0327
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0306

Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium

Research Committee(s)
Genitourinary Cancer
Activated
07-15-2003
Closed
02-01-2007
Closed
Phase
Accrual
92%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0317
Closed
Phase
Accrual
22%
Published
Closed
Phase
Accrual
48%
Published
SWOG Clinical Trial Number
S0030
Closed
Phase
Accrual
81%
Published
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0124
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0213
Closed
Phase
Accrual
84%
Published
SWOG Clinical Trial Number
S0215
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
97%
Published
SWOG Clinical Trial Number
S0120